On Tuesday, Supernus Pharmaceuticals Inc (NASDAQ: SUPN) was -3.27% drop from the session before settling in for the closing price of $32.75. A 52-week range for SUPN has been $25.53 – $40.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 11.80%. When this article was written, the company’s average yearly earnings per share was at -37.53%. With a float of $53.34 million, this company’s outstanding shares have now reached $55.74 million.
Let’s determine the extent of company efficiency that accounts for 674 employees. In terms of profitability, gross margin is 78.93%, operating margin of 11.52%, and the pretax margin is 14.79%.
Supernus Pharmaceuticals Inc (SUPN) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Supernus Pharmaceuticals Inc stocks. The insider ownership of Supernus Pharmaceuticals Inc is 4.43%, while institutional ownership is 108.76%. The most recent insider transaction that took place on Feb 21 ’25, was worth 36,292. In this transaction SVP, Chief Medical Officer of this company sold 927 shares at a rate of $39.15, taking the stock ownership to the 7,853 shares. Before that another transaction happened on Feb 04 ’25, when Company’s Sr. VP of IP, CSO sold 9,477 for $39.70, making the entire transaction worth $376,237. This insider now owns 10,149 shares in total.
Supernus Pharmaceuticals Inc (SUPN) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -37.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.66% during the next five years compared to -8.87% drop over the previous five years of trading.
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Trading Performance Indicators
You can see what Supernus Pharmaceuticals Inc (SUPN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.67. Likewise, its price to free cash flow for the trailing twelve months is 10.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.32, a number that is poised to hit 0.36 in the next quarter and is forecasted to reach 2.54 in one year’s time.
Technical Analysis of Supernus Pharmaceuticals Inc (SUPN)
Looking closely at Supernus Pharmaceuticals Inc (NASDAQ: SUPN), its last 5-days average volume was 0.37 million, which is a drop from its year-to-date volume of 0.56 million. As of the previous 9 days, the stock’s Stochastic %D was 35.26%. Additionally, its Average True Range was 1.12.
During the past 100 days, Supernus Pharmaceuticals Inc’s (SUPN) raw stochastic average was set at 13.22%, which indicates a significant decrease from 28.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.18% in the past 14 days, which was lower than the 40.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.90, while its 200-day Moving Average is $33.51. However, in the short run, Supernus Pharmaceuticals Inc’s stock first resistance to watch stands at $32.43. Second resistance stands at $33.19. The third major resistance level sits at $33.71. If the price goes on to break the first support level at $31.15, it is likely to go to the next support level at $30.63. Should the price break the second support level, the third support level stands at $29.87.
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Key Stats
There are 55,814K outstanding shares of the company, which has a market capitalization of 1.77 billion. As of now, sales total 661,820 K while income totals 73,870 K. Its latest quarter income was 174,160 K while its last quarter net income were 15,330 K.
